[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Akron Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,73,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609980","conventional-ultrafiltration-versus-dilutional-ultrafiltration-in-pediatric-cpb-patients-100609980",false,"NCT07221630","Conventional Ultrafiltration Versus Dilutional Ultrafiltration in Pediatric CPB Patients","Effects of Conventional and Dilutional Ultrafiltration Techniques During Cardiopulmonary Bypass in Pediatric Cardiac Patients","Inclusion Criteria:\n\n* Males and females less than 5 years of age\n* Cardiac operations utilizing CPB\n* Cardiac reoperations utilizing CPB\n\nExclusion Criteria:\n\n* Patients greater than 5 years of age.\n* Any active SYSTEMIC noncardiac disease expected to raise patient baseline CRP levels to above normal levels (\\>1mg\u002FdL). Since CRP levels correlate with the severity of most skin disease, patients with active dermatitis issues on the day of surgery will be excluded from the study. Patients with autoimmune diseases including RA, SLE, IBD (Crohn's disease, ulcerative colitis), Kawasaki disease and patients experiencing active infections will be excluded from the study.\n* Any noncardiac disease not well controlled (ex. Asthma not properly controlled with medication, etc.)\n* Recent viral illness (ex. Positive COVID\u002Fflu test 30 days prior to surgery)\n* All patients receive solumedrol (10mg\u002Fkg dose) from anesthesia as part of the prebypass protocol. Any patient currently taking steroids will also be excluded from the study\n* Non-cardiopulmonary bypass cases (Off pump CoA, Vascular ring surgery, etc.)\n* ECMO patients\n* Emergent cases",true,"ALL","1 Day","5 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","The investigators will be comparing two different filtration methods on cardiopulmonary bypass for pediatric heart surgery patients. Three blood tests will be taken from the patient to compare which filtration method is better at decreasing post-cardiopulmonary bypass inflammation caused by the heart-lung machine.",[26],"Systemic Inflammatory Response Syndrome",[28,29,30,31],"Dilutional Ultrafiltration","Conventional Ultrafiltration","Cardiopulmonary Bypass","C-reactive protein","NOT_YET_RECRUITING","2025-10-27",{"date":35,"type":36},"2025-10-28","ACTUAL",{"date":38,"type":22},"2026-01-01",{"date":40,"type":22},"2027-01-02",{"name":42,"class":43},"Akron Children's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100533499","phase-2-dupixent-in-adults-with-refractory-post-burn-pruritus-in-an-ambulatory-clinic-100533499","NCT06226610","Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic","A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic","Inclusion Criteria:\n\n• Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from standard of care (medical management by antihistamine and neuroleptic medications) after at least four weeks and are a minimum of four weeks after their last grafting surgery, and who speak English sufficient to participate in the study.\n\nExclusion Criteria:\n\n* Currently taking Dupixent for any other diagnosis\n* known allergy to Dupixent\n* pregnant and or lactating mothers\n* anyone treated for pruritus using laser therapy\n* currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications\n* Currently taking steroids\n* persons with developmental delays or otherwise unable to complete measures\n* prisoners or anyone otherwise unable to give their own consent or who is not their own guardian\n* one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder; gall bladder disorder; or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.\n* Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site\n* We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived benefit could confound our results.\n* We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.","18 Years","60 Years",{"count":55,"type":22},46,"INTERVENTIONAL",[58],"PHASE2","The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.",[61],"Pruritis",[63],"Itching, itch","RECRUITING","2025-09-16",{"date":67,"type":36},"2025-09-19",{"date":69,"type":36},"2024-11-21",{"date":71,"type":22},"2026-12-31",{"name":42,"class":43},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":56,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":44},"100573332","phase-4-safety-and-efficacy-of-subdermal-betadine-during-posterior-spinal-fusion-100573332","NCT06744907","Safety and Efficacy of Subdermal Betadine During Posterior Spinal Fusion","Subdermal Betadine to Reduce Microbacterial Bioburden During Posterior Spinal Fusion","Inclusion Criteria\n\n* Males and females\n* Undergoing primary posterior spinal fusion of the thoracic and\u002For lumbar spine\n* English Speaking\n\nExclusion Criteria\n\n* Patients who have undergone prior spinal surgery\n* Undergoing procedures other than primary posterior spinal fusion of the thoracic and\u002For lumbar spine (cervical fusion, anterior surgery, growth-friendly instrumentation)\n* Any contraindication to povidone-iodine, including pregnancy, allergy, or prior treatment with radioiodine","26 Years",{"count":82,"type":22},60,[84],"PHASE4","Bacterial in the subdermal layer of the skin, such as in hair follicles and sweat glands, may contaminate surgical wounds. The goal of this study is to learn about povidone-iodine and its ability to prevent infections specifically in patients with scoliosis receiving a spinal fusion.",[87],"Spinal Fusion",[87,89,90,91,92],"Lumbar Spine","Thoracic Spine","Subdermal Betadine","Microbacterial bioburden","2025-01-09",{"date":95,"type":36},"2025-01-13",{"date":97,"type":36},"2025-01-03",{"date":99,"type":22},"2026-11",{"name":42,"class":43},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":56,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100273314","pneumoperitoneum-management-with-surgiquest-airseal-at-low-vs-higher-pressure-100273314","NCT02837601","Pneumoperitoneum Management With SurgiQuest AirSeal® at Low vs. Higher Pressure","A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related To The Use Of The Surgiquest Airseal® Insufflation System (AIS) At Low Vs. Higher Pressure For The Management Of Pneumoperitoneum","PRESSURE","Inclusion Criteria:\n\n1. Pediatric subjects (\\\u003C21 years of age)\n2. \\> 20 kg in weight;\n3. Capable and willing to provide parental Informed Consent and patient Assent;\n4. Acceptable candidate for laparoscopic surgery;\n\nExclusion Criteria:\n\n1. Active cutaneous infection or inflammation;\n2. Pre-existing immunodeficiency disorder and\u002For chronic use of systemic steroids;\n3. Uncontrolled diabetes mellitus\n4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's disease or current platelet count \\\u003C 100,000 cells\u002Fmm3, baseline INR(international normalized ratio) ≥1.8, or fibrinogen level less than 150 mg\u002Fdl (if received a fibrinolytic agent within prior 24 hours);\n5. Severe co-existing morbidities having a life expectancy of less than 30 days;\n6. Currently involved in any other investigational clinical Studies;\n7. Significant anemia with a hemoglobin level less than 10 g\u002FdL or a hematocrit less than 30%;\n8. Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating;\n9. Extreme morbid obesity (BMI greater than 45 kg\u002Fm2)\n10. Patients presenting with Ascites","21 Years",{"count":111,"type":22},102,[113],"NA","A prospective, randomized, controlled single-center clinical Study designed to evaluate Physician Preference related to the use of the SurgiQuest AirSeal® Insufflation System (AIS) at low vs. higher pressures for the Management of pneumoperitoneum. Subjects will be randomized in a 1:1 treatment device to control ratio into one of two (2) different study arms:\n\n1. AIS with an insufflation pressure target of 9mmHg ±1mmHg; or\n2. AIS with an insufflation pressure target of 15mmHg ±1mmHg.",[116],"Shoulder Pain",[118,116,119,120],"Laparoscopic surgical procedures","Abdominal Pain","Pediatrics","2020-07-10",{"date":123,"type":36},"2020-07-13",{"date":125,"type":22},"2021-03",{"date":127,"type":22},"2027-11",{"name":42,"class":43},""]